| Austin Thomas Moster, DO | |
|
300 E Boyd Ave Ste 120, Greenfield, IN 46140-2832 | |
| (317) 462-3441 | |
| Not Available |
| Full Name | Austin Thomas Moster |
|---|---|
| Gender | Male |
| Speciality | Family Medicine |
| Location | 300 E Boyd Ave Ste 120, Greenfield, Indiana |
| Accepts Medicare Assignments | Medicare enrolled and may accept medicare through third-party reassignment. May prescribe medicare part D drugs. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1720616709 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 207Q00000X | Family Medicine | 02006951A (Indiana) | Primary |
| Entity Name | Hancock Physician Network, Llc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1609806470 PECOS PAC ID: 8325952633 Enrollment ID: O20040130000777 |
News Archive
ChemGenex Pharmaceuticals Limited and Hospira, Inc. announced today that they have entered into an exclusive agreement to license, develop and commercialize ChemGenex's product candidate omacetaxine mepesuccinate, a novel targeted cytotoxic pharmaceutical product, in Europe, the Middle East and parts of Africa (the Territory).
The Bariatric Metabolic Institute (BMI) at University of California, San Diego Health System has been accredited as a Level 1 facility by the Bariatric Surgery Center Network (BSCN) Accreditation Program of the American College of Surgeons (ACS). This designation means that the institutional performance of UC San Diego BMI meets the rigorous requirements outlined by the ACS BSCN Accreditation Program.
Peptimmune, Inc., a privately held biotechnology company, announced the completion of a clinical trial to evaluate the safety, tolerability, pharmacokinetics, and pharmacodynamics of PI-2301 in subjects with Secondary Progressive Multiple Sclerosis (SP-MS). PI-2301 is a novel peptide copolymer for the treatment of multiple sclerosis and other autoimmune diseases.
The Mount Desert Island Biological Laboratory has announced that assistant professor Sandra Rieger, Ph.D., has identified two drugs that could potentially be used to reverse peripheral nerve damage, or peripheral neuropathy, resulting from chemotherapy treatment for ovarian, breast, lung, pancreas and other cancers. The drugs also have potential applications for the treatment of peripheral nerve damage caused by diabetes, traumatic injuries and other conditions.
› Verified 7 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Austin Thomas Moster, DO 300 E Boyd Ave Ste 120, Greenfield, IN 46140-2832 Ph: (317) 462-3441 | Austin Thomas Moster, DO 300 E Boyd Ave Ste 120, Greenfield, IN 46140-2832 Ph: (317) 462-3441 |
News Archive
ChemGenex Pharmaceuticals Limited and Hospira, Inc. announced today that they have entered into an exclusive agreement to license, develop and commercialize ChemGenex's product candidate omacetaxine mepesuccinate, a novel targeted cytotoxic pharmaceutical product, in Europe, the Middle East and parts of Africa (the Territory).
The Bariatric Metabolic Institute (BMI) at University of California, San Diego Health System has been accredited as a Level 1 facility by the Bariatric Surgery Center Network (BSCN) Accreditation Program of the American College of Surgeons (ACS). This designation means that the institutional performance of UC San Diego BMI meets the rigorous requirements outlined by the ACS BSCN Accreditation Program.
Peptimmune, Inc., a privately held biotechnology company, announced the completion of a clinical trial to evaluate the safety, tolerability, pharmacokinetics, and pharmacodynamics of PI-2301 in subjects with Secondary Progressive Multiple Sclerosis (SP-MS). PI-2301 is a novel peptide copolymer for the treatment of multiple sclerosis and other autoimmune diseases.
The Mount Desert Island Biological Laboratory has announced that assistant professor Sandra Rieger, Ph.D., has identified two drugs that could potentially be used to reverse peripheral nerve damage, or peripheral neuropathy, resulting from chemotherapy treatment for ovarian, breast, lung, pancreas and other cancers. The drugs also have potential applications for the treatment of peripheral nerve damage caused by diabetes, traumatic injuries and other conditions.
› Verified 7 days ago
Thomas O'connor, MD Family Medicine Medicare: Accepting Medicare Assignments Practice Location: 300 E Boyd Ave, Suite 100, Greenfield, IN 46140 Phone: 317-462-5252 Fax: 317-462-8010 | |
Dr. Ray A Haas, MD Family Medicine Medicare: Not Enrolled in Medicare Practice Location: 120 W Mckenzie Rd, Suite H, Greenfield, IN 46140 Phone: 317-462-2335 Fax: 317-462-2069 | |
Bernard Richard, MD Family Medicine Medicare: Accepting Medicare Assignments Practice Location: 740 W Green Meadows Dr, Suite 105, Greenfield, IN 46140 Phone: 317-318-7777 Fax: 317-318-7700 | |
Dr. Mark E Lemmons, M.D. Family Medicine Medicare: Accepting Medicare Assignments Practice Location: 1515 N State St, Greenfield, IN 46140 Phone: 317-467-4300 Fax: 317-467-4302 | |
Stephanie J Kinnaman, MD Family Medicine Medicare: Accepting Medicare Assignments Practice Location: 300 E Boyd Ave, Suite 100, Greenfield, IN 46140 Phone: 317-462-5252 Fax: 317-462-8010 | |
Julia Degler, M.D. Family Medicine Medicare: Accepting Medicare Assignments Practice Location: 300 E Boyd Ave, Suite #120, Greenfield, IN 46140 Phone: 317-462-3441 Fax: 317-462-5476 | |
Amy R. Wooldridge, MD Family Medicine Medicare: Accepting Medicare Assignments Practice Location: 1 Memorial Sq Ste 305, Greenfield, IN 46140 Phone: 317-462-6662 Fax: 317-468-6275 |